Method of detecting signal clipping in a wearable ambulatory medical device
A wearable medical device and method of detecting clipping of ECG signals is disclosed. In one embodiment, the wearable medical device comprises a plurality of ECG sensing electrodes configured to sense an ECG of a patient and an ECG acquisition circuit electrically coupled to a pair of the plurality of ECG sensing electrodes and configured to provide an amplified and conditioned analog ECG signal, a programmable attenuation/gain stage electrically coupled between a first gain stage and a second gain stage, an ADC electrically coupled to the ECG acquisition circuit to receive and digitize the amplified and conditioned analog ECG signal and provide a digitized ECG signal, and a signal conditioning and control unit electrically coupled to the ECG acquisition circuit and the ADC to receive and monitor the digitized ECG signal and to detect clipping of the amplified and conditioned analog ECG signal based upon the digitized ECG signal.
1. A wearable medical device, comprising:
a plurality of ECG sensing electrodes configured to sense an ECG of a patient;
an ECG acquisition circuit electrically coupled to a pair of the plurality of ECG sensing electrodes and configured to provide an amplified and conditioned analog ECG signal, the ECG acquisition circuit including a programmable attenuation/gain stage electrically coupled between a first gain stage and a second gain stage;
an analog to digital converter electrically coupled to the ECG acquisition circuit to receive and digitize the amplified and conditioned analog ECG signal and provide a digitized ECG signal; and
a signal conditioning and control unit electrically coupled to the ECG acquisition circuit and the analog to digital converter to receive and monitor the digitized ECG signal, to detect clipping of the amplified and conditioned analog ECG signal based upon the digitized ECG signal, and to determine whether the clipping of the amplified and conditioned analog ECG signal occurred before or after the programmable attenuation/gain stage.
2. The wearable medical device of claim 1 , wherein the signal conditioning and control unit includes an automatic level control unit electrically coupled to the programmable attenuation/gain stage, and configured to vary an amount of attenuation/gain provided by the programmable attenuation/gain stage based on the digitized ECG signal.
3. The wearable medical device of claim 2 , wherein the automatic level control unit is configured to determine whether a voltage level of the digitized ECG signal is above a threshold level and configured to increase the amount of attenuation provided by the programmable attenuation/gain stage.
4. The wearable medical device of claim 2 , wherein the automatic level control unit is configured to determine whether a voltage level of the digitized ECG signal is below a threshold level and configured to decrease the amount of attenuation provided by the programmable attenuation/gain stage.
5. The wearable medical device of claim 2 , wherein the signal conditioning and control unit includes an analog clipping detection and control unit electrically coupled to the programmable attenuation/gain stage, and configured to determine whether a voltage level is approaching a clipping threshold.
6. The wearable medical device of claim 5 , wherein the analog clipping detection and control unit is configured to determine the voltage level before the programmable attenuation/gain stage.
7. The wearable medical device of claim 6 , wherein the amplified and conditioned analog ECG signal is marked as compromised in response to a determination that the voltage level is approaching the clipping threshold before the programmable attenuation/gain stage.
8. The wearable medical device of claim 5 , wherein the analog clipping detection and control unit is configured to determine the voltage level after the programmable attenuation/gain stage.
9. The wearable medical device of claim 8 , wherein the analog clipping detection and control unit attenuates the amplified and conditioned analog ECG signal in response to a determination that the voltage level is approaching the clipping threshold after the programmable attenuation/gain stage.
10. The wearable medical device of claim 5 , wherein the clipping threshold is determined based on a voltage range of an ECG of a human patient, a maximum output voltage level and a current gain setting of one of the first gain, the programmable attenuation/gain stage or the second gain stage.
11. The wearable medical device of claim 1 , further including a low noise instrumentation amplifier electrically coupled to the pair of the plurality of ECG sensing electrodes and the first gain stage.
12. The wearable medical device of claim 1 , further including a low pass filter electrically coupled to at least one of the second gain stage and the analog to digital converter.
13. The wearable medical device of claim 5 , wherein the clipping threshold is determined based on a voltage range of an ECG of a human patient, and a maximum output voltage level and a current gain setting of each of the first gain, the programmable attenuation/gain stage and the second gain stage.
14. The wearable medical device of claim 1 , wherein the first gain stage and the second gain stage comprise programmable gain/attenuation stages.
15. The wearable medical device of claim 12 , wherein the low pass filter comprises a programmable low pass filter having a programmable cutoff frequency that can be controlled by the signal conditioning and control unit.
16. The wearable medical device of claim 15 , wherein the signal conditioning and control unit is configured to lower the programmable cutoff frequency in response to a detection of high frequency noise causing clipping of the amplified and conditioned analog ECG signal.
17. The wearable medical device of claim 1 , wherein the signal conditioning and control unit is further configured to attenuate the amplified and conditioned analog ECG signal in response to a determination that a voltage level is approaching a clipping threshold after the programmable attenuation/gain stage and mark the amplified and conditioned analog ECG signal as compromised in response to a determination that the voltage level is approaching the clipping threshold before the programmable attenuation/gain stage.
18. A wearable medical device, comprising:
a plurality of ECG sensing electrodes configured to sense an ECG of a patient;
an ECG acquisition circuit electrically coupled to a pair of the plurality of ECG sensing electrodes and configured to provide an amplified and conditioned analog ECG signal, the ECG acquisition circuit including a programmable attenuation/gain stage electrically coupled between a first gain stage and a second gain stage;
an analog to digital converter electrically coupled to the ECG acquisition circuit to receive and digitize the amplified and conditioned analog ECG signal and provide a digitized ECG signal; and
a signal conditioning and control unit electrically coupled to the ECG acquisition circuit and the analog to digital converter to receive and monitor the digitized ECG signal and to determine whether a voltage level is approaching a clipping threshold based upon the digitized ECG signal, the clipping threshold being determined based on at least a voltage range of an ECG of a human patient, a maximum output voltage level and a current gain setting of each of the first gain stage, the programmable attenuation/gain stage and the second gain stage.
19. The wearable medical device of claim 18 , wherein the signal conditioning and control unit is further configured to determine whether the clipping of the amplified and conditioned analog ECG signal occurred before or after the programmable attenuation/gain stage.
20. The wearable medical device of claim 19 , wherein the signal conditioning and control unit is further configured to attenuate the amplified and conditioned analog ECG signal in response to a determination that a voltage level is approaching a clipping threshold after the programmable attenuation/gain stage and mark the amplified and conditioned analog ECG signal as compromised in response to a determination that the voltage level is approaching the clipping threshold before the programmable attenuation/gain stage.